In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology.
Otsuka has broken up with a clutch of clinical cancer candidates. The Japanese drugmaker said strategic reasons—the pharma equivalent of “it’s not you, it’s me”—underpinned the decision to ax the assets.
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition.
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the antibody-drug conjugate (ADC) last year, but investors sent Corbus’ stock down 10% in premarket trading.
Join us for an expert discussion on how to navigate complex DSCSA requirements in this rapidly advancing field. Explore the systems, processes and technologies that are crucial to safeguard patients.
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions.
After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team. President and CEO Henry Gosebruch is leaving the company effective Feb. 14, and will be replaced as CEO by co-founder Paul Berns and as president by Joshua Pinto, Ph.D.
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and inclusion page undergoes construction.
This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year.
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the autoimmune disease.
Bristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected state III and stage IV melanoma did not achieve its primary endpoint.
Immediately following Senate confirmation, Robert F. Kennedy Jr. has been named chair of the Make America Healthy Again Commission, which will be focused on chronic disease and transparency in medical research.
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi "expansion phase" on the horizon. And more.
This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year.
